Canales, Miguel A.Buchholz, Thomas A.Bortolini, Jaisson A. P.Fogliatto, Laura M.Ishikawa, TakayukiIzutsu, KojiSalar Silvestre, AntonioSharman, Jeff P.Klingbiel, DirkPokala, SunnyVorozheikina, EkaterinaTrask, PeterParreira, JoanaHübel, Kai2024-03-072024-03-072023Canales MA, Buchholz TA, Bortolini JAP, Fogliatto LM, Ishikawa T, Izutsu K, Salar A, Sharman JP, Klingbiel D, Pokala S, Vorozheikina E, Trask P, Parreira J, Hübel K. Obinutuzumab can be administered as a 90-minute short duration infusion in patients with previously untreated follicular lymphoma: Gazelle end of induction analysis. Hemasphere. 2023 Mar 30;7(4):e860. DOI: 10.1097/HS9.00000000000008602572-9241http://hdl.handle.net/10230/59340application/pdfeng© 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.Anticossos monoclonalsRituximabinfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1097/HS9.0000000000000860info:eu-repo/semantics/openAccess